Foghorn Therapeutics vs Voyager Therapeutics
Voyager Therapeutics is the larger business, with $40.4m of revenue in fiscal 2025 against $30.9m for Foghorn Therapeutics (1.3 times as much). Foghorn Therapeutics grew faster (36.8% against -49.5%). Foghorn Therapeutics kept more of each dollar of sales as profit: a net margin of -240.3% against -296.5%.
| Latest fiscal year | Foghorn TherapeuticsFHTX, 2025 | Voyager TherapeuticsVYGR, 2025 |
|---|---|---|
| Revenue | $30.9m | $40.4m |
| Revenue growth | 36.8% | -49.5% |
| Net income | −$74.3m | −$120m |
| Operating margin | -279.5% | -326.6% |
| Net margin | -240.3% | -296.5% |
| Return on equity | — | -48.3% |
| Free cash flow | −$86.1m | −$135m |
| Cash | $80.9m | $65.3m |
| Total debt | $0 | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 106 | 141 |
| Market value | $124m | $110m |
| Price vs our value range | — | — |
| Moat score | 14 (Weak) | 11 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 11 sales |